DeepMed Research

ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)

Not Applicable

Conditions: HIV-uninfected Children
HIV
Children Exposed to HIV

Interventions: Other: HIV-infected children initiated antiretroviral treatment within the first 7 months of life

First Posted Date: 2015-10-07

Last Posted Date: 2016-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 400

Registration Number: NCT02570334

Locations: 🇨🇲
Centre Hospitalier d'Essos, Yaounde, Cameroon
🇨🇲
Hôpital de Laquintinie, Douala, Cameroon
🇨🇲
Hôpital de la Fondation Mère-enfant Chantal Biya, Yaounde, Cameroon

Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France

Completed

Conditions: Chronic Hepatitis B
HIV Infection

First Posted Date: 2015-10-02

Last Posted Date: 2017-05-15

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 2468

Registration Number: NCT02566148

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: dolutegravir (Tivicay®) - Phase 1
Drug: lamivudine (Epivir®) - Phase 2
Drug: dolutegravir (Tivicay®) - Phase 2

First Posted Date: 2015-08-18

Last Posted Date: 2017-08-22

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 110

Registration Number: NCT02527096

Locations: 🇫🇷
Hôpital Bichat, Paris, France
🇫🇷
Hôpital Saint-André, Bordeaux, France
🇫🇷
Hôpital du Bocage, Dijon, France

and more 15 locations

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

Phase 2

Completed

Conditions: Hepatitis C
HIV Infection

Interventions: Drug: Sofosbuvir
Drug: Ribavirin
Drug: Ledipasvir

First Posted Date: 2015-04-01

Last Posted Date: 2017-12-13

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 120

Registration Number: NCT02405013

Locations: 🇨🇮
CHU de Youpougon - Service de Gastro-entéro-hépatologie, Abidjan, Côte D'Ivoire
🇨🇲
Clinique de la Cathédrale, Yaoundé, Cameroon
🇸🇳
CHU Fann, Service des Maladies Infectieuses, Dakar, Senegal

and more 1 locations

Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

Phase 2

Completed

Conditions: HIV INFECTION

Interventions: Drug: Darunavir

First Posted Date: 2015-03-10

Last Posted Date: 2017-01-24

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 100

Registration Number: NCT02384967

Locations: 🇫🇷
Hôpital Saint Louis, Paris, France

Qualification of Point-of-Care Assays for Management of HCV Patients

Conditions: Hepatitis C

First Posted Date: 2015-01-09

Last Posted Date: 2015-03-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 250

Registration Number: NCT02335320

Locations: 🇫🇷
Groupe Hospitalier Cochin Saint-Vincent de Paul, Paris, France

Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination

Completed

Conditions: Hepatitis B
HIV Infection

Interventions: Other: blood sampling

First Posted Date: 2014-12-23

Last Posted Date: 2014-12-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 55

Registration Number: NCT02323308

Locations: 🇫🇷
Chu Dijon, Dijon, France

Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

Phase 2

Withdrawn

Conditions: Hepatitis C Virus Genotype 4 Infection

Interventions: Drug: .Asunaprevir, Daclatasvir and BMS - 791325

First Posted Date: 2014-12-05

Last Posted Date: 2016-02-02

Lead Sponsor: ANRS, Emerging Infectious Diseases

Registration Number: NCT02309450

Locations: 🇫🇷
France, All the Regions of the Country, France

Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men

Not Applicable

Completed

Conditions: Hiv Infection

Interventions: Procedure: Standard proctologic examination
Procedure: High resolution anoscopy
Procedure: Biopsy(ies) during High Resolution Anoscopy
Procedure: High Resolution Anoscopy biannually

First Posted Date: 2014-11-11

Last Posted Date: 2024-08-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 516

Registration Number: NCT02287961

Locations: 🇫🇷
Diaconesses, Paris, France

Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Phase 3

Completed

Conditions: HIV-1 Infection
Tuberculosis

Interventions: Drug: Tenofovir + lamivudine + raltegravir
Drug: Tenofovir + lamivudine + efavirenz

First Posted Date: 2014-10-24

Last Posted Date: 2018-12-31

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 460

Registration Number: NCT02273765

Locations: 🇨🇮
PACCI / CePReF Centre de Prise en charge de Recherche et de Formation, Abidjan, Côte D'Ivoire
🇲🇿
Instituto Nacional de Saude / Hospital Geral de Machava, Maputo, Mozambique
🇧🇷
Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ, Rio de Janeiro, Brazil

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy